Alcohol-Disulfiram Reaction: MOA by System

Core Biochemical Mechanism (The Root Cause)

Ethanol  →[ADH]→  Acetaldehyde  →[ALDH]→  Acetic acid (harmless)

System-by-System MOA

🫀 Cardiovascular System

Danger: In patients with coronary artery disease or heart failure, severe hypotension and arrhythmias can be fatal.

🧠 Nervous System (Central & Autonomic)

🫁 Respiratory System

🤢 Gastrointestinal System

🫀 Hepatic System

🩸 Metabolic / Endocrine

👁️ Ophthalmological (rare/chronic)

Summary Timeline of the Reaction

High-Risk Populations (Contraindications)

• Heart disease (risk of MI, arrhythmia)
• Prior stroke (cerebral hypoperfusion)
• Diabetes mellitus (glucose dysregulation + cardiovascular risk)
• Hypertension (vascular instability)

Acamprosate & Naltrexone: Complete Pharmacology

ACAMPROSATE (Campral)

Core MOA — Glutamate/GABA Modulation

• Insomnia, anxiety, restlessness, dysphoria
• Craving driven by the "abstinence syndrome"

Acamprosate's Dual Action

• Acamprosate (calcium acetyl homotaurinate) is a structural analogue of GABA and taurine
• It binds to NMDA glutamate receptors and blocks them → reduces the pathological glutamate hyperactivity of protracted withdrawal
• Specifically acts at the glycine co-agonist site and polyamine modulatory site on NMDA receptors
• Net effect: dampens excitatory tone → reduces craving, anxiety, insomnia

• Has weak positive allosteric modulation of GABA-A receptors
• Augments inhibitory tone to further restore the excitatory/inhibitory balance disrupted by chronic alcohol

Pharmacokinetics

Clinical Use

• Indication: Maintenance of abstinence in alcohol-dependent patients after detox
• Does not help during active withdrawal
• Best for patients whose primary drive to relapse is protracted withdrawal symptoms (anxiety, dysphoria, insomnia)
• Started after detox; continued for 6–12 months
• Does not affect the reward/pleasure of drinking — it targets craving from dysphoria, not euphoria

Key Advantages

• Not hepatically metabolized → safe in liver disease (important in alcoholic patients)
• No abuse potential
• No significant drug interactions

Side Effects

• GI: diarrhea (most common), nausea, flatulence
• Headache, dizziness
• Rare: suicidal ideation (monitor)

NALTREXONE

Core MOA — Opioid Receptor Blockade → Dopamine Reward Blunting

The Reward Pathway Link to Alcohol:

Naltrexone Blocks This Cascade:

Alcohol ingestion
        ↓
Endogenous opioid (β-endorphin) release
        ↓
μ-opioid receptor activation in VTA
        ↓  ← NALTREXONE BLOCKS HERE
Disinhibition of dopamine neurons
        ↓
Dopamine ↑ in nucleus accumbens
        ↓
Pleasure / reward / craving reinforcement

• Decreases activity in the dopamine-rich ventral tegmental reward system
• Reduces the euphoric "high" from drinking — alcohol becomes less rewarding
• Reduces cue-induced craving (the anticipatory dopamine response)
• Shortens relapse duration — patients who do drink consume less

Pharmacokinetics

Clinical Use

• Indication: Alcohol use disorder (also opioid use disorder)
• Best for patients whose primary drive is the euphoric reward of alcohol
• Particularly effective in patients with strong family history of alcoholism (opioid-reward hypothesis — genetic high responders)
• The "Sinclair Method" uses naltrexone taken only before drinking ("targeted/as-needed" dosing) to extinguish conditioned reward

Key Advantages

• Once-monthly injection (Vivitrol) improves compliance
• Also treats opioid use disorder simultaneously
• Reduces relapse rates and drinking days

Contraindications & Warnings

• Acute hepatitis or liver failure — hepatotoxic at high doses (but hepatotoxicity uncommon at standard doses)
• Current opioid use — will precipitate acute opioid withdrawal (must be opioid-free for 7–10 days before starting)
• Opioid analgesics will be ineffective during emergencies → carry a medical alert card
• Pregnancy: Category C

Side Effects

• Nausea (most common — give with food)
• Headache, fatigue, dizziness
• Hepatotoxicity (at doses ≥5× therapeutic)
• Injection site reactions (IM form)
• Dysphoria (from opioid blockade)

Head-to-Head Comparison

Combination Therapy

• Naltrexone → blunts the reward of drinking
• Acamprosate → reduces the withdrawal-driven craving

Clinical Decision Framework

Alcohol Use Disorder patient in recovery
              ↓
Does patient relapse for the HIGH/EUPHORIA?
    YES → Naltrexone (reward pathway)
    NO → Does patient relapse due to anxiety/insomnia/dysphoria?
         YES → Acamprosate (protracted withdrawal)
              ↓
         Liver disease present?
              YES → Acamprosate preferred
         Renal failure present?
              YES → Naltrexone preferred
         Both? → Combination therapy